Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-01 pm EST
58.64 USD   +1.98%
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lantheus Holdings Shares Drop 10% After Planned Senior Notes Offering

12/05/2022 | 10:45am EST

By Chris Wack


Lantheus Holdings Inc. shares were down 10% to $55.21 Monday after the company said it intends to offer $500 million of convertible senior notes due 2027.

The notes will be offered and sold only to qualified institutional buyers, pursuant to Rule 144A under the Securities Act of 1933, the Massachusetts company said.

Initial purchasers may also be granted an option to purchase--within the 13-day period beginning on, and including, the initial closing date of the offering--up to an additional $75 million in aggregate principal amount of notes.

The notes will be senior unsecured obligations of the company, fully and unconditionally guaranteed on a senior unsecured basis by Lantheus Medical Imaging Inc., a direct wholly owned subsidiary of the company.

The notes will mature on Dec. 15, 2027, unless earlier redeemed, repurchased or converted, and are expected to pay interest semi-annually in arrears, the company said.

Lantheus said it intends to use a portion of the proceeds for general corporate purposes, including repurchases of its common stock from time to time in an amount up to $75 million, working capital, capital expenditures, refinancing and debt repayment.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

12-05-22 1044ET

All news about LANTHEUS HOLDINGS, INC.
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for..
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
AQ
01/11Lantheus Holdings Seeks M&A
CI
01/11Transcript : Lantheus Holdings, Inc. Presents at 41st Annual J.P. Morgan Heal..
CI
01/11Lantheus Holdings, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/04Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
GL
2022Lantheus Holdings, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,..
AQ
2022Point Biopharma, Lantheus Close Licensing Deals for Cancer Treatment Candidates
MT
2022Lantheus Holdings, Inc. : Completion of Acquisition or Disposition of Assets, Other Events..
AQ
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 917 M - -
Net income 2022 200 M - -
Net Debt 2022 - - -
P/E ratio 2022 20,8x
Yield 2022 -
Capitalization 3 958 M 3 958 M -
Capi. / Sales 2022 4,32x
Capi. / Sales 2023 3,81x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 58,64 $
Average target price 100,33 $
Spread / Average Target 71,1%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors